HKHasan Karanlik

Hasan Karanlik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hasan Karanlik has a total of 328 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Surgical Margin Width Does Not Impact Local Recurrence Across Tumor Subtypes After Neoadjuvant Systemic Treatment and Breast‐Conserving Surgery

    by Adela‐Luciana Oprea, Canan Aral, Yusuf Emre Aytin, Suleyman Bademler, Hasan Karanlik, M. Umit Ugurlu, Atakan Sezer, Tiberiu‐Bogdan Szekely, Rares Georgescu, Bahadir M. Gulluoglu

    Introduction: Neoadjuvant systemic treatment (NAST) is the standard of care for patients with large tumors and/or regional lymph node involvement, particularly in those with HER2‐positive or triple‐negative breast cancer. A key advantage of NAST is tumor downstaging, which facilitates breast‐conserving surgery (BCS). However, the impact of surgical margin width on local recurrence rates across different tumor subtypes remains unclear. Methods: This study retrospectively evaluated the rate of in‐breast invasive tumor recurrence (IITR) following BCS in patients of all tumor subtypes who received NAST. Patients with T 1–4a–c N 0–1 M 0 breast cancer who received NAST followed by BCS and locoregional radiotherapy were included. Two comparisons were performed: (1) patients with IITR versus those without, to identify factors related to recurrence; and (2) patients within each tumor subtype, to examine IITR rates according to surgical margin width. Results: Among 429 patients (median age 48 years; range, 26–75) with a median follow‐up of 55 months (range, 4–199), IITR occurred in 16 patients (3.7%). IITR rates were similar across subtypes: 2.8% ( n = 6) in HR+/HER2−, 6.3% ( n = 5) in HR+/HER2+, 4.0% ( n = 2) in HR−/HER2+, and 3.7% ( n = 3) in triple‐negative tumors. No significant difference in IITR rates was found when stratified by surgical margin width within each subtype. Younger patient age was the only factor significantly associated with IITR. Breast cancer–specific mortality was significantly higher among patients with HR−/HER2+ and triple‐negative tumors compared with those with HR + tumors. Conclusion: IITR was infrequent among patients undergoing BCS after NAST. Minimal clear margins (no ink on tumor) were found to be safe across all tumor subtypes in cases without complete response to NAST. Younger age was independently associated with higher IITR risk, regardless of margin width or tumor subtype.

  • Open Access

    Locoregional Treatment in De Novo Bone-Only Metastatic Breast Cancer: Prospective, Multi-Institutional Real-World Data, BOMETIN, Protocol MF14-1a

    by Atilla Soran, Berk Göktepe, Berkay Demirors, Ozgur Aytac, Serdar Ozbas, Lutfi Dogan, Didem Can Trablus, Jamila Al-Azhri, Kazım Senol, Shruti Zaveri, et al.

    Introduction: The impact of locoregional treatment (LRT) on survival in de novo bone-only metastatic breast cancer (dnBOMBC) is controversial. This study aims to assess the effect of LRT on survival, utilizing international, prospectively acquired data in this cohort of patients. Materials and Methods: Patients with dnBOMBC were divided into two groups: those receiving systemic therapy only (ST) and those undergoing LRT. Further, patients who received LRT were divided into two subgroups: those who received ST after LRT (LRT+ST group) and those who received ST prior to LRT (ST+LRT group). Factors associated with disease progression, including solitary or multiple bone metastases, were analyzed. Results: There was a total of 744 patients with dnBOMBC treated at each of the participating institutions between 2014 and 2022, with 372 (50%) participants in each arm. Median follow-up was 48 months (32–66, 25–75%). Patients in the LRT group were significantly younger than the ST group [50 (42, 60) vs. 55 (44, 66), p = 0.0001]. There were no significant differences in grade, HER2 status, triple-negative status, receipt of hormonal therapy, or intervention to metastatic sites. During follow-up, 58% (n = 217) of patients in the ST group and 32% (n = 120) of patients in the LRT group died (p < 0.001). Local progression was observed in 20% of the patients in the ST group, whereas 9% progressed in the LRT group (p = 0.0001). Systemic progression occurred more in the ST group; 66% (n = 244) compared to 41% (n = 152) of patients in the LRT group (p < 0.001). The hazard of death was 64% lower in the LRT group than in the ST group (HR: 0.36, 95% CI: 0.29–0.45, p < 0.0001). The burden of metastatic disease differed significantly between the two groups, with a higher rate of solitary bone metastases in the LRT group compared to the ST group (50% vs. 24%, p < 0.001). However, the LRT group had better overall survival (OS) for both solitary (HR: 0.38, 95% Cl: 0.26–0.55) and multiple (HR: 0.38, 95% Cl: 0.29–0.51) bone metastasis patients. Within the LRT group, survival rates were similar whether the breast surgery was performed before or after ST. Multivariate Cox analysis showed that LRT and ER/PR positivity significantly decrease the hazard of death (p < 0.05). Conclusions: Analysis of this large multi-institutional patient cohort provides further evidence that LRT is associated with longer OS and lower locoregional recurrence rates in patients with dnBOMBC. In breast cancer patients with bone-only metastases at presentation, the decision for LRT should be made through a multidisciplinary approach with consideration of surgical therapy at the primary tumor.


  • Open Access

    Accuracy of Intraoperative Sentinel Lymph Node Evaluation by Imprint Cytology in Breast Cancer: A 12-Year Single Center Experience With 2,528 Patients

    by Aysel Bayram, Sidar Bagbudar, Cagla Safak Karaoglan, Esma Sayar, Baran Mollavelioglu, Mustafa Tukenmez, Hasan Karanlık, Semen Onder, Ekrem Yavuz

    Accuracy of Intraoperative Sentinel Lymph Node Evaluation by Imprint Cytology in Breast Cancer: A 12-Year Single Center Experience With 2,528 Patients - European Journal of Breast Health


  • Open Access

    Loco-Regional Treatment in De Novo Bone Only Metastatic Breast Cancer; Prospective, Multi-Institutional Real-World Data, BOMETIN, Protocol MF14-1a

    by Atilla Soran, Berk Göktepe, Berkay Demirors, Ozgur Aytac, Serdar Özbaş, Lutfi Dogan, Didem Can Trabulus, Jamila Al-Azhri, Kazim Senol, Shruti Zaveri, et al.

    Introduction: The impact of loco-regional treatment (LRT) on survival in de novo bone-only metastatic breast cancer (dnBOMBC) is controversial. The aim of this study is to assess the effect of LRT on survival utilizing international, prospectively acquired data in this cohort of patients. Materials and Methods: Patients with dnBOMBC were divided into two groups: those receiving systemic therapy only (ST) and those undergoing LRT. Further, patients who received LRT were divided into two subgroups: those who received ST after LRT (LRT+ST group) and those who received ST prior to LRT (ST+LRT group). Factors associated with disease progression including solitary or multiple bone metastases were analyzed. Results: There was a total of 744 patients with dnBOMBC treated at each of the participating institutions between 2014 and 2022, with 372 (50%) participants in each arm. Median follow-up was 48 months (32-66, 25-75%). Patients in the LRT group were significantly younger than the ST group [50 (42, 60) vs. 55 (44, 66), p=0.0001]. There were no significant differences in grade, HER2 status, triple-negative status, receipt of hormonal therapy, or intervention to metastatic sites. During follow-up, 58% (n=217) of patients in ST group and 32% (n=120) of patients in LRT group died (pConclusion: Analysis of this large multi-institutional patient cohort provides further evidence that LRT improves OS and lowers loco-regional recurrence in patients with dnBOMBC. In breast cancer patients with bone-only metastases at presentation, the decision for LRT should be made through a multidisciplinary approach with consideration of surgical therapy at the primary tumor.


  • Role of Sentinel Lymph Node Biopsy with Blue Dye Only after Neoadjuvant Systemic Treatment in Patients with Breast Cancer Who Had Biopsy-Proven Node-Positive Disease at Admission: SENATURK-ROSANNA Study

    by Aysegul Aktas, Meryem Gunay Gurleyik, Guldeniz Karadeniz Cakmak, Hasan Karanlik, Sibel Ozkan Gurdal, M. Umit Ugurlu, Atakan Sezer, Bahadir M. Gulluoglu

    Introduction: In breast cancer patients with initially metastatic axillary lymph nodes (pN+, ALNs), neoadjuvant systemic treatment (NST) significantly downstages axillary disease. Sentinel lymph node biopsy (SLNB) in well-responded patients has been associated with high false-negative rates (FNRs) when less than 3 nodes are retrieved and a single tracer is used. Targeted axillary dissection after node clipping has been proposed to reduce FNR but is costly, is labor intensive, and requires specialized equipment. However, there is limited evidence linking high FNR with worse long-term oncological outcomes, such as recurrence rates. This study evaluates axillary recurrence rates in breast cancer patients downstaged by NST and assessed with SLNB using blue dye alone. Methods: We retrospectively analyzed clinical, pathological, and follow-up data from 245 breast cancer patients treated between 2010 and 2021 across six centers in Turkiye. All patients had pN+, ALNs at diagnosis and were downstaged to ypN0 or ypN0[i+] by SLNB with blue dye after NST. Recurrence rates in the breast, axilla, other regional lymphatics, distant organs, and mortality were recorded. Results: Of the 245 patients, 10% had cN2 disease and 35% had less than 3 sentinel lymph nodes retrieved. After SLNB, 6% had isolated tumor cells in their nodes, while the rest achieved a pathologic complete response. The median follow-up was 51 months. Only 2% developed ipsilateral axillary recurrence (0.8% isolated), and 18% had any recurrence, primarily as distant metastasis. The mortality rate was 9%. Conclusion: Our study demonstrates that performing SLNB after NST using only blue dye may be a viable and acceptable approach in clinical practice. The oncological safety and adequacy of this simple method should be confirmed with further studies.


  • Open Access

    Long-term oncologic safety of one-stage direct-to-implant immediate breast reconstruction without the use of acellular dermal matrix

    by Berkay Kılıç, Burak İlHan, Hasan Karanlık

    Aim: This study aimed to evaluate the oncologic safety of direct-to-implant immediate breast reconstruction without the use of an acellular dermal matrix (ADM) or mesh following nipple-sparing and skin-sparing mastectomy in patients with primary breast cancer. Materials and Methods: The medical records of 175 patients who underwent one-stage direct-to-implant breast reconstruction following mastectomy at the Istanbul University Oncology Institute between 2014 and 2022 were retrospectively reviewed. The primary objective was to assess the oncologic safety, including locoregional recurrence, distant metastasis, and survival outcomes. The secondary objective was to evaluate reconstruction-related complications. Results: The median age of the patients was 44 years (range: 25-74), with a median follow-up period of 53 months (range: 19-101). HR+/HER2-, HR+/HER2+, and pure HER2+ subtypes were observed in 101 patients (57.7%), 26 (14.9%), 23 (13.%), respectively. Triple-negative breast cancer was present in 16 patients (9.1%). Neoadjuvant chemotherapy was administered to 87 patients (49.7%), with a pathological complete response (pCR) rate of 17.2%. Skin necrosis (9.1%) and capsular contracture (8.6%) were the most common complications, with implant loss occuring in seven patients. Locoregional recurrence and distant metastasis rates were 9.7% and 13.1%, respectively. The five-year locoregional recurrence-free survival and distant metastasis-free survival rates were 95.4% and 90.3%. Additionally, 83.5% of patients reported their satisfaction as "excellent" or "good." Conclusion: One-stage direct-to-implant immediate breast reconstruction without the use of an acellular dermal matrix or mesh is oncologically safe, with acceptable complication rates, making it a viable alternative to two-stage breast reconstruction or conventional mastectomy.

  • Open Access

    Totally implantable venous access devices: A fifteen-year single-center experience

    by Berkay Kılıç, Burak İlHan, Hasan Karanlık

    Objectives: Totally implantable venous access devices (TIVADs) are frequently used in cancer patients, offering significant comfort and advantages. This study aims to evaluate the outcomes of patients who underwent port catheter placement. Methods: Data from 3,774 patients who underwent venous port catheter placement between 2007 and 2022 were reviewed. Demographic information, primary diagnoses, port placement locations, number of punctures, complications, and reasons for removal were recorded. Results: The median age of the patients was 54 years (range: 18-86 years). Catheters were placed on the right side in 3,667 patients (97.2%). The most commonly used vessel was the right subclavian vein, accessed in 2,494 patients (66.1%). Complication rates were observed as follows: femoral vein (40%), brachial vein (20%), subclavian vein (12.1%), internal jugular vein (9.9%), and external jugular vein (6.5%). The complication rate following a single puncture was 7.4%, compared to 16.1% for multiple punctures, showing a significant increase with the number of punctures (P=0.03). The most common early complication in 142 (3.8%) patients was arterial puncture with bleeding or hematoma, while the most common late complication was catheter infection of 1.4% (n=54). Conclusions: Venous port catheter placement is generally safe, with the right subclavian vein being the most commonly used site. Ultrasound-guided placement reduces complications, which are more frequent with multiple punctures and left-side placements. Early complications like arterial puncture were more common, while late complications were primarily catheter infection.


  • Open Access

    Factors Predicting Additional Residual Nodal Disease With a Metastatic Sentinel Node Biopsy or Targeted Axillary Dissection After Neoadjuvant Chemotherapy

    by Neslihan Cabıoğlu, Hasan Karanlık, Abdullah Iğci, Mahmut Müslümanoğlu, Okan Mustafa Gürsoy, Mustafa Tükenmez, Nusret Can Polat, Enver Özkurt, Selman Emiroğlu, Nilüfer Yıldırım, et al.

    Cabıoğlu N, et al. J Breast Cancer. 2025 Aug;28:e26. https://doi.org/10.4048/jbc.2025.0052